Effect of bosentan therapy in persistent pulmonary hypertension of the newborn

Persistent pulmonary hypertension of the newborn (PPHN) contributes to neonatal hypoxemia and is associated with a high mortality. Some PPHN patients are unresponsive to inhaled nitric oxide (iNO). Bosentan, an oral endothelin-1 receptor antagonist, reduces pulmonary vascular resistance and hence may play a role in the treatment of PPHN.

Source: Pediatrics and Neonatology - July 19, 2017 Category: Perinatology & Neonatology Authors: Gunlawadee Maneenil, Anucha Thatrimontrichai, Waricha Janjindamai, Supaporn Dissaneevate Tags: Original Article Source Type: research